Staidson Beijing Biopharma (300204) — Net Asset Momentum
Staidson Beijing Biopharma (300204) recorded a net asset momentum of -12.0% as of December 2025, with net assets of CN¥806.72 Million CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See 300204 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Staidson Beijing Biopharma Net Asset Momentum (2007–2025)
This chart tracks Staidson Beijing Biopharma's year-over-year net asset growth across 19 annual reporting periods from 2007 to 2025. The most recent momentum reading is -12.0%, with net assets of CN¥806.72 Million CNY as of December 2025. Read 300204 liabilities breakdown for a breakdown of total debt and financial obligations.
Annual Net Asset History for Staidson Beijing Biopharma (2007–2025)
The table below shows the complete annual net asset history for Staidson Beijing Biopharma from 2007 to 2025, covering 19 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see 300204 market cap.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | CN¥806.72 Million | CN¥1.27 Billion | CN¥459.48 Million | ▼ -12.0% |
| 2024 | CN¥916.76 Million | CN¥1.15 Billion | CN¥232.85 Million | ▼ -10.2% |
| 2023 | CN¥1.02 Billion | CN¥1.33 Billion | CN¥311.55 Million | ▼ -24.6% |
| 2022 | CN¥1.35 Billion | CN¥1.67 Billion | CN¥315.45 Million | ▼ -12.7% |
| 2021 | CN¥1.55 Billion | CN¥1.83 Billion | CN¥276.25 Million | ▼ -2.3% |
| 2020 | CN¥1.59 Billion | CN¥1.86 Billion | CN¥268.70 Million | ▼ -2.9% |
| 2019 | CN¥1.64 Billion | CN¥1.86 Billion | CN¥227.18 Million | ▼ -33.5% |
| 2018 | CN¥2.46 Billion | CN¥2.77 Billion | CN¥314.30 Million | ▲ +11.2% |
| 2017 | CN¥2.21 Billion | CN¥2.63 Billion | CN¥419.14 Million | ▲ +15.2% |
| 2016 | CN¥1.92 Billion | CN¥2.35 Billion | CN¥432.32 Million | ▲ +13.9% |
| 2015 | CN¥1.68 Billion | CN¥2.07 Billion | CN¥387.06 Million | ▲ +11.2% |
| 2014 | CN¥1.51 Billion | CN¥1.81 Billion | CN¥297.54 Million | ▲ +15.2% |
| 2013 | CN¥1.31 Billion | CN¥1.57 Billion | CN¥255.47 Million | ▲ +5.9% |
| 2012 | CN¥1.24 Billion | CN¥1.43 Billion | CN¥192.15 Million | ▲ +12.6% |
| 2011 | CN¥1.10 Billion | CN¥1.15 Billion | CN¥47.32 Million | ▲ +563.0% |
| 2010 | CN¥166.23 Million | CN¥264.88 Million | CN¥98.66 Million | ▲ +38.9% |
| 2009 | CN¥119.72 Million | CN¥148.75 Million | CN¥29.03 Million | ▲ +90.6% |
| 2008 | CN¥62.82 Million | CN¥92.07 Million | CN¥29.25 Million | ▲ +85.5% |
| 2007 | CN¥33.87 Million | CN¥82.22 Million | CN¥48.35 Million | — |